cyrilzakka/clinical-trials huggingface dataset:
Multidisciplinary Rehabilitation After Cancer Pulmonis Operation

The purpose of this investigation is to determine the effects of exercise training on quality of life and physical capacity, 3 months and 1 year after radical operation for pulmonary cancer.

Patients who are radically operated for pulmonary cancer report suffering from respiratory problems, mostly dyspnoea, 5 years after operation. Dyspnoea restricts their physical capability and leads to poorer physical, social and mental wellbeing. The effects of training programs on physical and mental wellbeing for cancer patients are well documented. Most of the studies are though performed on patients suffering from breast, colon and prostate cancer. There are only few studies addressing patients with pulmonary cancer. They are mostly focused on short term effects of exercise training on quality of life, with no control group included in the trials. These studies target patients after different forms for treatment, including surgery, chemotherapy and radiation. There is no data referring to quality of life of patients who are radically operated for pulmonary cancer.

Comparison: multidisciplinary group intervention consisting of exercise training and dyspnoea counseling, 10 times, once a week, compared with one instruction in exercise training and dyspnoea counseling. Exercise training is given by a physiotherapist. Both groups receive in addition standard treatment, which is up to 3 counseling sessions with a nurse.

Eligibility Criteria:
Inclusion Criteria:

* patients who are radically operated for pulmonary cancer at Aalbor Hospital, Aarhus University Hospital

Exclusion Criteria:

* not radically operated
* cannot speak and read Danish
* cannot cooperate in tests due to poor mental health
* patients who undergo rehabilitation at other centres
* cannot perform walking test due to physical impairment
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease

This is a clinical research study of interferon (IFN) plus chemotherapy with the standard combination of Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD). The treatment will be given to patients with Hodgkin's disease. The study will look at whether adding IFN to ABVD improves the immune response against Hodgkin's disease, and will determine whether the toxicity of ABVD is increased by adding IFN.

Each treatment cycle will last 2 weeks. On days 1 - 4 of each cycle, patients will be given a shot of IFN under the skin. On day 4, patients will be given ABVD through a vein over one-hour.

The plan is for patients to receive 12 cycles of treatment. However, patients will leave the study if they have severe side effects or if the cancer grows or spreads. They will also leave if the cancer does not improve after 6 cycles. Patient who leave the study will be offered other treatments. A maximum of 35 patients will be treated with that dose.

Before the first treatment, patient will have a physical exam, blood tests, and a heart scan. Within 1 month of starting treatment, patients will have a chest X-ray, CT scans of the abdomen and pelvis, and a gallium scan.

During the study, patient will have blood tests every week and a physical exam every 2 weeks. The X-ray, CT scans, and gallium scan will be repeated after cycles 6 and 12.

All the drugs in this study are approved by the U.S. Food and Drug Administration and are available by prescription. ABVD is a standard treatment for Hodgkin's disease; IFN is an investigational treatment for Hodgkin's disease. About 35 patients will be enrolled in the study. All treatment will be given in the outpatient clinic at M.D. Anderson Cancer Center.

Eligibility Criteria:
Inclusion Criteria:

1. Hodgkin's disease patients who relapse after radiation therapy alone, or in combination with Novantrone, Oncovin, Velban, and Prednisone (NOVP); and previously untreated patients with stage III and IV who are eligible for standard ABVD therapy.
2. Must have adequate bone marrow reserve Absolute neutrophil count (ANC) \> 1,000/uL, Platelets \> 100,000
3. Left ventricular ejection fraction (LVEF) \>/= 50%, serum creatinine \< 2mg/dl, serum bilirubin \< 2mg/dl

Exclusion Criteria:

1. No prior therapy with Mustargen Oncovin Procarbazine Prednisone (MOPP).
2. No severe pulmonary disease including Chronic obstructive pulmonary disease (COPD) and asthma.
Effects and Safety of Menthol on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients

Prehypertension and mild hypertension are associated with an increased risk of atherosclerosis and coronary artery disease, and often complicated with the metabolic disorder of glucose and lipid. The comprehensive prevention of hypertension is still an important and complex clinical issue. Peppermint is a popular flavoring agent, and peppermint tea help relax tension and could lower blood pressure. The effect of oral peppermint on blood pressure is not consistent, however, our previous animal study has shown that oral administration of menthol, the main component of peppermint, could reduce 24-hour mean arterial systolic and diastolic blood pressure in spontaneous hypertensive rats. Furthermore, menthol increases uncoupling protein(UCP)1 dependent thermogenesis and energy expenditure through transient receptor potential melastatin(TRPM)8 activation, and helps prevent obesity and metabolic disorders. In a prospective, double-blind, randomized, and parallel-group study, we will evaluate the effects of DANSHU capsule(menthol) on blood pressure and metabolic parameters in prehypertensive and mild hypertensive patients. This study will help develop future comprehensive prevention and treatment strategies for hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Blood pressure: 120mmHg≤SBP\<160mmHg, and/or 80mmHg≤DBP\<100mmHg

Exclusion Criteria:

* Diabetes
* Hypertension: SBP≥160mmHg, or DBP≥100mmHg
* known allergy to trial drugs
* Myocardial infarction or cerebrovascular accident in the year preceding the trial
* Clinical Congestive Heart Failure
* Secondary hypertension
* Pregnancy or lactating women
* Malignant tumor
* Gastroesophageal reflux or gastroduodenal ulcer
* History of hepatitis or cirrhosis
* History of kidney disease
* Body weight﹤35Kg
Incidence of Metabolic Syndrome and Thyroid Dysfunction in Patients With Major Depressive Disorder

Aim 1 is to study prevalence and 1 year incidence of metabolic syndrome in major depressive disorder and factors correlation.

Aim 2 is to study prevalence and 1 year incidence of thyroid dysfunction in major depressive disorder and factors correlation.


Eligibility Criteria:
Inclusion Criteria:

* patient with major depressive disorder
* age over 18 years

Exclusion Criteria:

* subject who cannot give information.
Trial of Terbutaline for the Treatment of Status Asthmaticus in Children

Although widely used for the treatment of pediatric status asthmaticus, intravenous terbutaline has potentially significant side effects; may not improve outcomes; and may increase Intensive Care Unit (ICU) length of stay. This study is designed to test the efficacy of intravenous terbutaline for the treatment of status asthmaticus by adding intravenous terbutaline or placebo to standard asthma treatment. The dose of terbutaline or placebo will be titrated according to severity of illness as quantified by a validated clinical asthma score. Differences in outcomes between the study groups, such as length of stay, hospital costs, and lung function will be compared.


Eligibility Criteria:
Inclusion Criteria:

* Admission to the Connecticut Children's Medical Center (CCMC) Pediatric Intensive Care Unit (PICU) with a primary admission diagnosis of status asthmaticus
* Modified Pulmonary Index Score (MPIS) of greater than or equal to 12
* Age between birth and 18 years old

Exclusion Criteria:

* Pre-existing cardiac or pulmonary disease
* Existing respiratory failure (requiring invasive or non-invasive mechanical ventilation)
* Hemodynamic or cardiovascular instability requiring inotropic support
* The patient meets one of the criteria for withdrawal from the study due to patient safety concerns
TVTO™ X TVTS ™ for Treatment of Stress Urinary Incontinence

This is a prospective, comparative randomized controled trial. The general purposes of this study is to compare the efficacy and safety of TVTO™ and TVTSecur™ as surgical treatment for female urinary stress incontinence.


Eligibility Criteria:
Inclusion Criteria:

* Clinical and urodynamic for stress urinary

Exclusion Criteria:

* Detrusor overactivity (urodynamic study)
* Urodynamic changes suggesting reduced vesical capacity
* Associated neurological diseases
* Coagulopathies
* Pregnancy
* Foreign matter sensitiveness history
* Acute urinary tract infection
* Sequel from high ionizing radiation exposure
* Use of drugs that may result in high surgical risk and/or significant postoperative complication
* Anesthetic procedure contraindication
* Vulvovaginitis: presence of vaginal secretion with infection clinically or lab supported
Pediatric Trauma Centers RE-AIM at Gun Safety

Universal firearm injury and violence prevention counseling of parents and patients has been recommended by multiple national organizations for over a decade, yet clinicians rarely deliver this counseling. Barriers to its implementation must be addressed in order to effectively deliver firearm related injury prevention efforts. This study will implement a universal firearm injury prevention initiative within a national cohort of three pediatric trauma centers. The investigator's long-term goal is to demonstrate best practices for pediatric trauma center-based firearm injury prevention strategies that promote safe storage practices and reduce firearm related injury and death. This research will test the effectiveness of a comprehensive training strategy for improving the implementation of a universal firearm injury prevention effort, ACTFAST (Adopting Comprehensive Training for FireArm Safety in Trauma centers), to 1) increase the adoption, implementation and sustainability of a universal firearm injury prevention initiative within participating pediatric level 1 trauma centers; 2) increase firearm safety knowledge, attitudes and safe firearm storage practices among parents of pediatric trauma patients and youth patients treated within participating pediatric level 1 trauma centers, and 3) increase trauma center clinicians' firearm safety knowledge and confidence in delivering a firearm safety intervention.


Eligibility Criteria:
For parents/guardians of pediatric trauma patients:

Inclusion Criteria:

* live with an admitted pediatric trauma patient at a participating trauma center
* be fluent in English or Spanish

Exclusion Criteria:

- family members who do not live with the admitted pediatric trauma patient

For youth trauma patients:

Inclusion Criteria:

* Must be between the ages of 11-17 years
* admitted to a participating trauma inpatient service for an injury
* fluent in English or Spanish
* able to provide written assent and parent able to provide written consent

Exclusion Criteria:

* Youth who are prisoners or in police custody
* Youth who are admitted due to suicide attempt
* Youth with acute conditions that would preclude provision of informed consent (i.e., acute psychosis, altered mental status, cognitive impairment)
ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study

The aim of the study is:

* Epidemiological/observational: investigating the presence of neuropsychological and electrophysiological alterations, suggesting a condition of minimal hepatic encephalopathy(and its behavioral correlates), in childhood and young adulthood affected by pre-hepatic portal hypertension due to portal vein thrombosis, even for implementing specific diagnostic protocols.
* Interventional: collecting preliminary data on the effects of a probiotic, in order to implement a controlled clinical study.

Epidemiological/observational study investigating the presence of neuropsychological and electrophysiological alterations, suggesting a condition of minimal hepatic encephalopathy(and its behavioral correlates), in childhood and young adulthood affected by pre-hepatic portal hypertension due to portal vein thrombosis, even for implementing specific diagnostic protocols

Eligibility Criteria:
Inclusion Criteria:

* extra-hepatic portal vein thrombosis
* 4-20 years
* knowledge of italian language
* absence of perceptive or communicative deficit
* absence of psychiatric disease or mental retardation

Exclusion Criteria:

* medical contraindications for required evaluations
* infective pathologies
* parenchymal hepatic pathologies
Screening for Uterine Cavity Abnormalities in Women Scheduled for IVF

Evaluation of the endometrial cavity is an important step in the infertility work-up, particularly if assisted reproductive therapy is planned. The aim is to identify possible endometrial abnormalities that may impair implantation.Undiagnosed endometrial abnormalities are present in 11 to 45% of women scheduled for in vitro fertilization (IVF).Traditionally, two dimensional transvaginal ultrasound (2D TVUS) and hysterosalpingography (HSG) are the basic methods for assessment of the endometrial cavity. However, these imaging modalities have shown high false negative rates among infertile women, a finding that could confine their rule to initial screening rather than definite diagnosis.

Office hysteroscopy (OH) is the gold standard for evaluation of the endometrial cavity. Although the endoscopic approach has been proven to increase pregnancy rate in women who experienced prior implantation failure, evidence on treatment of unsuspected hysteroscopically-diagnosed endometrial lesions, to improve IVF outcome, is still lacking. Nevertheless,clinicians tend to use OH routinely prior to IVF because the psychological and financial burden that infertile couples may experience as a consequence of failed IVF cycle is unjustifiable.Yet, costs and invasiveness of OH counteract its global implementation to all women prior to IVF.


Eligibility Criteria:
Inclusion Criteria:

* History of primary infertility
* Normal uterine cavity on HSG
* Women were selected for IVF therapy.

Exclusion Criteria:

* Women with known diagnosis of uterine abnormality by office hysteroscopy
Cochlear Implantation Among Adults and Older Children With Unilateral or Asymmetric Hearing Loss

Do adults and children over 7 years of age with unilateral or assymetric hearing loss benefit from cochlear implantation on the worst hearing side.

Unilateral hearing loss is known to impair binaural hearing abilities. Specifically, localization, speech understanding in noise, and binaural squelch suffer due to lack of binaural timing and level cues. This study is designed to examine how binaural hearing is improved following cochlear implantation on the impaired side. The study endpoints are collected at 6 months and 12 months post activation of the implant.

This is not a funded study. All costs are billed through insurance for reimbursement. There is an insurance approval process that we move through after a participant has been evaluated at the Mayo Clinic and found to be a candidate for cochlear implantation.

Eligibility Criteria:
Adults

* 18 years of age or older,
* Hearing loss in the ear to be implanted must such that speech understanding is not possible with a well fitted hearing aid. Specifically, less than 40% monosyllabic word understanding when that ear is tested in the best-aided condition and the other ear is sufficiently occluded or masked.
* Onset of hearing loss in the adult group must be post-lingual (after three years of age)

Children

* Children 7 years of age and older
* Hearing loss in the ear to be implanted configured such that word understanding is less 40% in the best aided condition
* Onset of hearing loss in the pediatric group must be post-lingual (after three years of age)
Preferences & Treatment Satisfaction Drivers in Rosacea Patients

To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.


Eligibility Criteria:
Inclusion Criteria:

* Male or female patients of at least 18 years of age at index date
* At least one prescription for a topical rosacea treatments: Azelaic Acid Gel, Azelaic Acid Cream, Metronidazole Gel, Metronidazole Cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
* At least one medical record with a diagnosis code for rosacea (ICD-9: 695.3)
* At least 6 months of data history prior to the index date
* Had at least one encounter at the Reliant Medical Group within 3 months prior to 01 January 2015

Exclusion Criteria:

* None
Multicenter Retrospective Study on Patients Treated with Stereotactic Radiosurgery/Radiotherapy for Single Brain Lesions: Evaluation of Treatment Efficacy and Safety, Also Through Radiomic Analysis Methods.

The study design concerns all patients diagnosed witha singular brain metastasis who underwent stereotactic radiosurgery/radiotherapy between January 2010 and December 2022

The study will include patients of both sexes diagnosed with single brain metastases who underwent radiosurgical/stereotactic treatment. Attention will be paid to data related to local control, potential recurrence, and/or radionecrosis. Once a sufficient number of treated patients is reached, the feasibility of a radiomic feature analysis will be assessed in order to identify potential correlations and/or predictive values for treatment response or radionecrosis. If the sample size is adequate, participating centers will be asked to share pre- and post-RT MRI (brain MRI with contrast using thin slices) and treatment volumes for radiomic evaluation.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Treatment with SRS/SRT techniques for a single secondary brain lesion
* Availability of pre-RT brain MRI with contrast (1mm slice thickness)
* Availability of CT simulation imaging for treatment
* Availability of relevant clinical data in the medical record for the study's objectives
* Follow-up of at least 6 months after the completion of SRS or SRT
* Follow-up evaluation through brain MRI

Exclusion Criteria:

* Age under 18 years
* Lack of clinical/radiological data for the patient
* Unavailability of the required imaging
* Previous whole-brain radiotherapy treatment
Transverse Versus Longitudinal Groin Incision in Vascular Surgery

The purpose of the study is to examine whether incision type has an influence on the development of groin wound complications after operation in the groin in vascular surgery.

The main questions it aims to answer are:

Does a transverse incision in the groin lead to fewer surgical site complications than a longitudinal incision? Does a transverse incision lead to fewer readmissions, fewer reoperations, shorter length of hospital stay, and a lower amputation rate.

Participants will undergo vascular surgery in the groin with either a transverse or longitudinal incision. The incision type will be selected randomly.


Eligibility Criteria:
Inclusion Criteria:

• Patients undergoing vascular reconstruction with a groin incision

Exclusion Criteria:

* Patients previously operated with a groin incision.
* Patients undergoing operation due to trauma, bleeding, or pseudoaneurysm.
* Patients operated within the first 24 hours of admission.
* If it prior to the operation is deemed necessary with a muscleplasty.
Can Doctors Reduce COVID-19 Misinformation and Increase Vaccine Uptake in Ghana? A Cluster-randomised Controlled Trial

Whilst Ghana was one of the first countries to start vaccinating its population against COVID-19, less than 30% of the population was fully vaccinated at the end of 2022. To improve COVID-19 vaccine uptake, the government has so far relied on two strategies: sensitization in communities and specific national vaccination days. Against the backdrop of strict budget constraints and the return to normalcy in health-seeking behaviours, the investigators aim to test the effectiveness of leveraging interactions of patients with the healthcare system to reduce misinformation and increase vaccination. The investigators collaborate with the Ghana Health Service to offer vaccination as a default option during routine consultations. To dispel information and encourage vaccination uptake effectively, the investigators test two interventions designed to encourage and equip front-line providers with skills to discuss COVID-19 vaccination with patients. The study evaluates the effect of the two interventions in a cluster-randomised trial where the investigators allocate 120 facilities to one of three groups: a control group where providers are not asked to offer COVID-19 vaccines; a light engagement group, where providers receive information about COVID-19 and vaccines and a light-touch vaccine monitoring device is deployed in their facility, and a communication skills building group, where providers receive all the elements of the light intervention, plus training in motivational engagement techniques to encourage vaccination. The primary outcome will be vaccination uptake and intentions. The study will also evaluate the impact of the intervention on patients' knowledge, beliefs and satisfaction. The investigators will track the effectiveness of the training on providers as well as the extent to which they apply their training to actual practice. Results will contribute to a nascent evidence base on potential ways to encourage adult vaccination during routine consultations.


Eligibility Criteria:
Inclusion Criteria:

* Mentally sound adults who are aged 16 years and above
* Presenting at the health centre on the day of surveys

Exclusion Criteria:

* Received a COVID-19 vaccination dose within last 6 months, or received 2 or more doses
* Have fever, chills, or are experiencing severe pain
A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers

This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst


Eligibility Criteria:
Inclusion Criteria:

* Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception
* BMI 18.0\~28.0 kg/m2
* Willing to provide written informed consent and to comply with study requirements
* On a stable diet for at least 4 weeks with no plans to significantly alter diet or weight over course of study
* TG\> 100 mg/dL
* LDL-C\> 70 mg/dL

Exclusion Criteria:

* Clinically significant health concerns
* Regular use of alcohol within one month prior to screening
* Recent (within 3 months) use of illicit drugs
* Female with pregnancy or breastfeeding
* QTcF\>450 ms in ECG
* Donation or loss of whole blood more than 400 ml prior to administration of the study treatment

Note: additional inclusion/exclusion criteria may apply, per protocol